BTKi combined with chemical immunotherapy in the initial treatment of aggressive mantle cell lymphoma: A retrospective study

Qianqian Ju,Zhenling Li

DOI: https://doi.org/10.1097/md.0000000000040197

IF: 1.6

2024-10-30

Medicine

Abstract:Mantle cell lymphoma (MCL) is a rare type of B-cell-derived non-Hodgkin's lymphoma. In Europe and the United States, the overall incidence of MCL is about 0.5 per 100,000 people, accounting for 2% to 10% of all non-Hodgkin lymphomas. [ 1 ] In recent years, the incidence of MCL has shown an increasing trend, [ 1 ] which may be related to the improvement of diagnostic levels. The male-to-female ratio is 2.3 to 2.5:1, and the median age of diagnosis is about 70 years in Europe and the United States. [ 1 ] The median age of onset of MCL in China was 58 years, accounting for 3.07% of the total lymphoma, [ 2 ] with a male-to-female ratio of about 2:1. [ 2 ] MCL combines the clinical presentation of aggressive lymphoma with the therapeutic response of inert lymphoma and is still a disease with an unmet therapeutic need. Current National Comprehensive Cancer Network guidelines, European Society for Medical Oncology (ESMO) guidelines, and Chinese Society Of Clinical Oncology (CSCO) guidelines, although there is no standard treatment for first-line MCL, have reduced the status of R-cyclophosphamide + aclarubicin + vincristine + prednisone (CHOP) or CHOP-like protocols. In fit patients with age, younger than 65 years old, rituximab in combination with high-dose Ara-C followed by is recommended, followed by 12 courses of rituximab maintenance once every 2 months after completion of treatment, which results in more than 6 years of median survival and a higher 5-year overall survival (OS). [ 3–5 ] For patients older than 65 years old and with non-transplantable initial treatment, bendamustine + rituximab (BR) or rituximab + bendamustine + Ara-C + cyclophosphamide, can be used for early induction therapy to improve patients' progression-free survival (PFS) and improve treatment efficiency. In addition, rituximab maintenance therapy has been shown to significantly prolong PFS in MCL. [ 6 ] Bruton's tyrosine kinase inhibitor (BTKi) is a novel small-molecule targeted drug that has been shown to have excellent efficacy as a single agent in relapsed MCL. The combination of BTKi with other drugs and its application in first-line MCL has also been reported. Ibrutinib treatment in combination with BR significantly prolonged PFS. The median PFS as assessed by the investigators was 80.6 months in the ibrutinib group, as compared with 52.9 months in the placebo group. [ 7 , 8 ] At present, there are few reports about the clinical application of BTKi combined with chemical immunotherapy in patients with initial MCL in China, especially about patients younger than 65 years old, who accepted rituximab combination with high-dose Ara-C. To meet the clinical needs of MCL patients, this study investigated the effect of advancing the use of BTKi in combination with chemotherapy.

medicine, general & internal